Compare VNRX & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | JSPR |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 23.1M |
| IPO Year | 2012 | N/A |
| Metric | VNRX | JSPR |
|---|---|---|
| Price | $0.16 | $0.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $2.00 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 17.2M | 562.8K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,727,384.00 | N/A |
| Revenue This Year | $479.89 | N/A |
| Revenue Next Year | $538.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.04 | N/A |
| 52 Week Low | $0.15 | $0.62 |
| 52 Week High | $0.94 | $7.19 |
| Indicator | VNRX | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 33.98 | 39.95 |
| Support Level | N/A | N/A |
| Resistance Level | $0.27 | $1.44 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 5.66 | 43.95 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.